Publications by authors named "Peter van Meer"

Claim this Profile
R
Retrospective evaluation of the use of non-human primates for fertility assessment of pharmaceuticals submitted for marketing approval in the EU.
Puck Roos, Diann L Blanset, Peter Jk van Meer, Shermaine Mitchell-Ryan, Peter T Theunissen

Regul Toxicol Pharmacol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From guideline to practice: three years of ICH S11 insights and recommendations.
Diana Tavares, Hsiao-Tzu Chien, Maria Elzbieta Sheean, Peter Theunissen, Peter van Meer

Front Med (Lausanne)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The devolution of biosimilars regulations.
Erik Doevendans, Peter van Meer, Huub Schellekens

Nat Biotechnol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of rat and rabbit embryofetal development studies with pharmaceuticals: the added value of a second species.
Puck Roos, Caroline Anggasta, Aldert H Piersma, Peter J K van Meer, Peter T Theunissen

Crit Rev Toxicol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Greater Flexibility for Chronic Toxicity Study Designs to Support Human Safety Assessment While Balancing 3Rs Considerations.
Helen Prior, Paul Baldrick, David O Clarke, Elisa Passini, Fiona Sewell, Peter van Meer

Int J Toxicol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of weight-of-evidence approaches to characterize developmental toxicity risk for therapeutic monoclonal antibodies in humans without in vivo studies.
Hsiao-Tzu Chien, Puck Roos, Frans G M Russel, Peter T Theunissen, Peter J K van Meer

Regul Toxicol Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A roadmap towards a human-centric safety assessment of advanced therapy medicinal products.
Hsiao-Tzu Chien, Victoria C de Leeuw, Joantine C J van Esterik, Frans G M Russel, Anne S Kienhuis, Peter van Meer

Regul Toxicol Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs.
Guilherme S Ferreira, Francis M Dijkstra, Désirée H Veening-Griffioen, Wouter P C Boon, Huub Schellekens, Peter J K van Meer

Transl Psychiatry· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach.
Hsiao-Tzu Chien, Helen Prior, Laura Andrews, Leon van Aerts, Annick Cauvin, Peter van Meer

Regul Toxicol Pharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
Helen Prior, Laura Andrews, Annick Cauvin, Hsiaotzu Chien, David O Clarke, Peter van Meer

Regul Toxicol Pharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tradition, not science, is the basis of animal model selection in translational and applied research.
Désirée H Veening-Griffioen, Guilherme S Ferreira, Wouter P C Boon, Christine C Gispen-de Wied, Huub Schellekens, Peter J K Van Meer

ALTEX· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applicability of organ-on-chip systems in toxicology and pharmacology.
Marlon R Schneider, Michael Oelgeschlaeger, Tanja Burgdorf, Peter van Meer, Peter Theunissen

Crit Rev Toxicol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Animal-free applications in the development of cell-based therapies.
Peter van Meer, Peter Theunissen, Tineke van den Hoorn, Carla Herberts, Jan Willem van der Laan

Br J Clin Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency.
Marieke J H J Dekker, Sieta T de Vries, Carolien H M Versantvoort, Ellen G E Drost-van Velze, Mansi Bhatt, Peter J K van Meer

Front Med (Lausanne)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Carlijn R Hooijmans, Ellen H M Moors, Peter J K van Meer

Eur J Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levelling the Translational Gap for Animal to Human Efficacy Data.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Peter J K van Meer

Animals (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A standardised framework to identify optimal animal models for efficacy assessment in drug development.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Christine C Gispen-de Wied, Peter J K van Meer

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease.
Désirée H Veening-Griffioen, Guilherme S Ferreira, Peter J K van Meer, Wouter P C Boon, Christine C Gispen-de Wied

Eur J Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development.
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Christine C Gispen-de Wied, Peter J K van Meer

PLoS One· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta-epidemiological study of randomized trials.
Tessa A Hulshof, Sytse U Zuidema, Peter J K van Meer, Christine C Gispen-de Wied, Hendrika J Luijendijk

Int J Methods Psychiatr Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.
Peter J K van Meer, Melanie L Graham, Henk-Jan Schuurman

Eur J Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of animal studies to evaluate the similarity of biosimilars to reference products.
Peter J K van Meer, Hans C Ebbers, Marlous Kooijman, Christine C Gispen-de Wied, Beatriz Silva-Lima

Drug Discov Today· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
Peter J K van Meer, Marlous Kooijman, Vera Brinks, Christine C Gispen-de Wied, Beatriz Silva-Lima

MAbs· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.
Hans C Ebbers, Peter J K van Meer, Ellen H M Moors, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens

Drug Discov Today· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ability of animal studies to detect serious post marketing adverse events is limited.
Peter J K van Meer, Marlous Kooijman, Christine C Gispen-de Wied, Ellen H M Moors, Huub Schellekens

Regul Toxicol Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis